Cargando…
Tixagevimab/cilgavimab pre-exposure prophylaxis and breakthrough infection risk in vaccinated solid organ transplant recipients: concern for immortal time bias effect
Autores principales: | Riggs, Julie M., Charya, Ananth V., Eberlein, Michael H., Reed, Robert M., Saharia, Kapil K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9829030/ https://www.ncbi.nlm.nih.gov/pubmed/36695703 http://dx.doi.org/10.1016/j.ajt.2022.11.021 |
Ejemplares similares
-
Response to letter entitled: Tixagevimab/cilgavimab pre-exposure prophylaxis and breakthrough infection risk in vaccinated solid organ transplant recipients: Concern for immortal time bias effect
por: Al Jurdi, Ayman, et al.
Publicado: (2023) -
Tixagevimab and cilgavimab for COVID-19 prophylaxis
Publicado: (2022) -
Pre-exposure Prophylaxis with Tixagevimab-cilgavimab did not Reduce Severity of COVID-19 in Lung Transplant Recipients with Breakthrough Infection
por: Sindu, Devika, et al.
Publicado: (2023) -
Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave
por: Al Jurdi, Ayman, et al.
Publicado: (2022) -
Tixagevimab + Cilgavimab: First Approval
por: Keam, Susan J.
Publicado: (2022)